• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Harnessing ARNI in advanced CKD - a new frontier for cardiac and renal protection.

作者信息

Maaz Umair, Hussain Fatima, Asghar Muskan, Adnan Saman

机构信息

Rahbar Medical and Dental College, Lahore, Pakistan.

Rawalpindi Medical University, Rawalpindi, Pakistan.

出版信息

Int Urol Nephrol. 2025 Apr;57(4):1353-1354. doi: 10.1007/s11255-024-04279-z. Epub 2024 Nov 7.

DOI:10.1007/s11255-024-04279-z
PMID:39509035
Abstract
摘要

相似文献

1
Harnessing ARNI in advanced CKD - a new frontier for cardiac and renal protection.在晚期慢性肾脏病中应用ARNI——心脏和肾脏保护的新领域。
Int Urol Nephrol. 2025 Apr;57(4):1353-1354. doi: 10.1007/s11255-024-04279-z. Epub 2024 Nov 7.
2
Angiotensin Receptor-Neprilysin Inhibitor for Chronic Kidney Disease: Strategies for Renal Protection.血管紧张素受体-脑啡肽酶抑制剂治疗慢性肾脏病：肾脏保护策略。
Kidney Blood Press Res. 2024;49(1):916-932. doi: 10.1159/000541939. Epub 2024 Oct 11.
3
Renal safety and efficacy of angiotensin receptor-neprilysin inhibitor: A meta-analysis of randomized controlled trials.血管紧张素受体-脑啡肽酶抑制剂的肾脏安全性和疗效：一项随机对照试验的荟萃分析。
J Clin Pharm Ther. 2020 Dec;45(6):1235-1243. doi: 10.1111/jcpt.13243. Epub 2020 Aug 10.
4
Sacubitril/valsartan reduces proteinuria depending on blood pressure in patients with stage 4-5 chronic kidney disease.在4-5期慢性肾脏病患者中，沙库巴曲缬沙坦降低蛋白尿的程度取决于血压水平。
Clin Exp Nephrol. 2024 Dec;28(12):1327-1331. doi: 10.1007/s10157-024-02561-z. Epub 2024 Oct 3.
5
Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study.血管紧张素受体-中性肽链内切酶抑制剂用于射血分数降低的心力衰竭合并晚期慢性肾脏病患者：一项回顾性多机构研究
Front Cardiovasc Med. 2022 Mar 8;9:794707. doi: 10.3389/fcvm.2022.794707. eCollection 2022.
6
Updates for Cardio-Kidney Protective Effects by Angiotensin Receptor-Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection.血管紧张素受体-脑啡肽酶抑制剂对心肾保护作用的更新：需要更多肾脏保护证据。
J Am Heart Assoc. 2023 Apr 18;12(8):e029565. doi: 10.1161/JAHA.122.029565. Epub 2023 Apr 17.
7
Clinical Response and Safety of Angiotensin Receptor and Neprilysin Inhibitor Combination in Advanced Chronic Kidney Disease and Heart Failure with Reduced Ejection Fraction.血管紧张素受体-脑啡肽酶抑制剂联合治疗射血分数降低的慢性肾脏病及心力衰竭的临床疗效及安全性观察
J Assoc Physicians India. 2023 Jul;71(7):11-12. doi: 10.59556/japi.71.0262.
8
"Renalism" with Renin Angiotensin Aldosterone System Inhibitor Use in Patients Enrolled in Trials for Heart Failure with Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Systematic Review.“肾素-血管紧张素-醛固酮系统抑制剂使用与射血分数降低的心力衰竭和晚期慢性肾脏病患者入组临床试验的相关性”：一项系统评价。
Curr Vasc Pharmacol. 2023;21(2):106-110. doi: 10.2174/1570161121666230314114549.
9
Consensus Statement from India on the Renal Benefits of ARNi, SGLT-2i, and Bisoprolol in Chronic Kidney Disease.印度关于 ARNi、SGLT-2i 和比索洛尔在慢性肾脏病中的肾脏获益的共识声明。
J Assoc Physicians India. 2024 May;72(5):77-88. doi: 10.59556/japi.72.0543.
10
Combination of sacubitril/valsartan and blockade of the PI3K pathway enhanced kidney protection in a mouse model of cardiorenal syndrome.沙库巴曲缬沙坦与PI3K通路阻断联合使用可增强心肾综合征小鼠模型的肾脏保护作用。
Eur Heart J Open. 2023 Sep 29;3(6):oead098. doi: 10.1093/ehjopen/oead098. eCollection 2023 Nov.

本文引用的文献

1
Risk stratification by renal function and NYHA class in patients with hypotension initiated on sacubitril/valsartan: a retrospective cohort study from 17 centres in Japan.在低血压患者中，根据肾功能和 NYHA 分级进行风险分层：来自日本 17 个中心的回顾性队列研究。
Open Heart. 2024 Oct 21;11(2):e002764. doi: 10.1136/openhrt-2024-002764.
2
Sacubitril/valsartan reduces proteinuria depending on blood pressure in patients with stage 4-5 chronic kidney disease.在4-5期慢性肾脏病患者中，沙库巴曲缬沙坦降低蛋白尿的程度取决于血压水平。
Clin Exp Nephrol. 2024 Dec;28(12):1327-1331. doi: 10.1007/s10157-024-02561-z. Epub 2024 Oct 3.
3
Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure.
沙库巴曲缬沙坦在心力衰竭患者肾功能损害谱中的作用。
J Am Coll Cardiol. 2024 Jun 4;83(22):2148-2159. doi: 10.1016/j.jacc.2024.03.392. Epub 2024 Apr 6.
4
The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis.沙库巴曲缬沙坦在慢性肾脏病中的疗效和安全性：系统评价和荟萃分析。
Int Urol Nephrol. 2024 Jan;56(1):181-190. doi: 10.1007/s11255-023-03599-w. Epub 2023 May 17.
5
Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.沙库巴曲缬沙坦对比奥美沙坦治疗日本原发性高血压患者的疗效：一项随机、双盲、多中心研究。
Hypertens Res. 2022 May;45(5):824-833. doi: 10.1038/s41440-021-00819-7. Epub 2022 Jan 21.
6
Efficacy of medication therapy for patients with chronic kidney disease and heart failure with preserved ejection fraction: a systematic review and meta-analysis.药物治疗对射血分数保留的慢性肾脏病和心力衰竭患者的疗效：系统评价和荟萃分析。
Int Urol Nephrol. 2022 Jun;54(6):1435-1444. doi: 10.1007/s11255-021-03025-z. Epub 2021 Oct 20.
7
Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease.肾素-血管紧张素系统抑制剂治疗射血分数保留的心力衰竭合并轻度至中度慢性肾脏病患者的疗效。
Eur J Prev Cardiol. 2018 Aug;25(12):1268-1277. doi: 10.1177/2047487318780035. Epub 2018 May 29.
8
Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.一流的血管紧张素受体脑啡肽酶抑制剂LCZ696在日本高血压合并肾功能不全患者中的安全性和有效性。
Hypertens Res. 2015 Apr;38(4):269-75. doi: 10.1038/hr.2015.1. Epub 2015 Feb 19.